Begin main content

Patient Input and Clinical Experts: Luxturna

March 25, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name Luxturna Generic name voretigene neparvovec Manufacturer Novartis Pharmaceuticals Canada Inc. Indication(s) Vision loss, inherited retinal dystrophy Project Number SR0643-000 Call for patient ...

COVID-19: An Update From Dr. Brian O’Rourke, CADTH President and CEO

March 18, 2020
For the latest updates and guidance on COVID-19, please consult the Public Health Agency of Canada. As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the risks to our staff and ensure that we continue to support Canada’s health care decision-makers during this period. Public health authorit...

Drug Reimbursement Recommendation - tafamidis (Vyndaqel)

February 21, 2020
Today, CADTH has issued final recommendations for: tafamidis (Vyndaqel) Indications: transthyretin-mediated amyloidosis Recommendation: Reimburse with clinical criteria and/or conditions For more information

Call for Feedback: Rituximab to Treat Primary Membranous Nephropathy

February 13, 2020
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders. Rituximab to Treat Primary Membranous Nephropathy Call for Feedback: 2020-02-13 Feedback Due By: 2020-02-28 Consultation Document: Proposed Project Scope Product Type: Health Technology Assessment Submit Feedback